Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402511 | 0.86 | BACE1 (0.40) | BACE1LMNANPC1RAB9AMAPT | |
| SCHEMBL12763609 | 0.86 | TRPA1 (0.40) | TRPA1BACE1CYP1A2CYP2A6LMNA | |
| SCHEMBL6989300 | 0.85 | BACE1 (0.39) | BACE1CYP1A2LMNAMAPTMAPK1 | |
| SCHEMBL8055086 | 0.85 | BACE1 (0.39) | BACE1LMNANPC1RAB9AMAPT | |
| SCHEMBL13226806 | 0.85 | TRPA1 (0.39) | TRPA1BACE1CYP1A2CYP2A6LMNA | |
| SCHEMBL8773286 | 0.85 | TRPA1 (0.43) | TRPA1BACE1CYP1A2CYP2A6LMNA | |
| SCHEMBL3690355 | 0.85 | BACE1 (0.47) | BACE1TAAR1GAA | |
| SCHEMBL13617385 | 0.85 | CYP4F2 (0.51) | BACE1CYP1A2LMNAMAPTMAPK1 | |
| SCHEMBL23365944 | 0.83 | SLC6A4 (0.45) | TRPA1CYP1A2CYP2A6ALDH1A1MAPT | |
| SCHEMBL6181671 | 0.83 | BACE1 (0.38) | BACE1LMNANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098416-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2012-07-26 | — | — | WO | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | TRPA1 4205/4885BACE1 595/4885CYP1A2 1596/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | TRPA1 1954/4885BACE1 108/4885CYP1A2 3491/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885BACE1 165/4885CYP1A2 763/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | TRPA1 4064/4885BACE1 175/4885CYP1A2 804/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | TRPA1 3839/4885BACE1 165/4885CYP1A2 763/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | TRPA1 4001/4885BACE1 373/4885CYP1A2 311/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885BACE1 165/4885CYP1A2 763/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | TRPA1 4001/4885BACE1 373/4885CYP1A2 311/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | TRPA1 1512/4885BACE1 83/4885CYP1A2 212/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885BACE1 165/4885CYP1A2 763/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | TRPA1 4021/4885BACE1 181/4885CYP1A2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.